Skip to main content
MSLE logo

MSLE

Satellos Bioscience Inc.
$8.98 +0.77 (+9.38%) At close · Jul 8
Market Cap
$196.65M
Shares
20,831,190

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$8.98 Open$8.70 Day$8.66–9.60 52W$4.64–13.40 Avg vol 30d54K Short int70K · 0.3% float · 1.9d Short vol74% DataJan 2020–Jul 2026
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 16.9 · calm Equity put/call 0.86
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +20%
above
Price vs 50-day avg +29%
above
RSI (14) 72
overbought
MACD trend Positive
52-week position 50%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +48%
trailing
6-month return +22%
trailing
YTD return +53%
this year
Relative strength +15%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.34% of float · ▼ -8.6% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Squeeze score 29
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −57%
past year
ATR 7.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+20% Bullish
Price vs 50-day avg
+29% Bullish
RSI (14)
72 Bearish
MACD trend
Positive Bullish
52-week position
50% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $7 › 200d $7 — 200d above 50d
Institutional flow Accumulating
+31 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.34% of float · ▼ -8.6% MoM · 1.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $5 Now $9 · 50% 52-wk high $13
vs 200-day avg +20% vs 50-day avg +29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MSLE
Satellos Bioscience Inc.
this stock
$196.65M +52.7% 0.3%
ONC
BeOne Medicines Ltd.
$437.67B -0.6% +22179.2% 890.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$126.01B +9.9% +46.2% 29.5 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$70.03B -14.0% +20.8% 16.3 3.2%
ARGX
Argenx SE
$56.84B +8.8% 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
31
% held
36.5%
Net QoQ
+7.6M sh
Top holder
Qiming U.S. Healthcare Fu…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
70.2K
Days to cover
1.9d
Change
-6.6K sh
View
Short Volume
Short vol %
74%
As of
Jul 9, 2026
Short Total
View
Fails to Deliver
FTD shares
2.2K
Value
$15.2K
As of
Jun 3, 2026
View
Off-Exchange
Off-exchange %
43.8%
Week of
May 4, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Jul 8, 2026
This year
22
View
Exempt Offerings
Offering
$25.0M
Filed
Jan 3, 2025
View
Earnings & Events
Earnings Calls
Last call
Jun 25, 2026
View
Investor Relations
Latest news
Satellos Reports Six-Month Interi…
Published
Jul 8, 2026
View

Performance

5D 20D 120D MTD YTD
MSLE +15.5% +47.7% +22.3% +15.5% +52.7%
SPY -0.2% +0.8% +7.4% -0.2% +9.3%
vs SPY +15.7% +46.9% +14.8% +15.7% +43.4%
Key facts CIK 1421642 CUSIP 80401L803 Visit website Investor relations